Fulcrum Therapeutics (FULC) News Today $3.22 -0.03 (-0.92%) Closing price 04:00 PM EasternExtended Trading$3.22 +0.00 (+0.16%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research DealMarch 5 at 7:44 PM | benzinga.comFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceMarch 4 at 4:05 PM | globenewswire.comEquities Analysts Offer Predictions for FULC Q1 EarningsMarch 2, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Outlook for FULC EarningsMarch 2, 2025 | americanbankingnews.comHC Wainwright Issues Negative Estimate for FULC EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Fein now expects that the company will post earniMarch 1, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook for FULC Q1 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.35) per sMarch 1, 2025 | marketbeat.comBrokers Set Expectations for FULC FY2029 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.95) per share for the yeaFebruary 28, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Earns "Neutral" Rating from HC WainwrightFebruary 28, 2025 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from BrokeragesShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned a consensus rating of "Hold" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assignedFebruary 28, 2025 | marketbeat.comOpCo reiterates Outperform on Fulcrum given bullish vibes ahead of SCD readoutFebruary 27, 2025 | markets.businessinsider.comFulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...February 27, 2025 | finance.yahoo.comPiper Sandler Sticks to Its Buy Rating for Fulcrum Therapeutics (FULC)February 27, 2025 | markets.businessinsider.comFulcrum Therapeutics Full Year 2024 Earnings: EPS Misses ExpectationsFebruary 27, 2025 | finance.yahoo.comFulcrum Therapeutics' (FULC) "Neutral" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "neutral" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Wednesday.February 26, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comFulcrum Therapeutics (NASDAQ:FULC) Issues Earnings ResultsFulcrum Therapeutics (NASDAQ:FULC - Get Free Report) released its earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).February 25, 2025 | marketbeat.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024February 25, 2025 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024February 25, 2025 | globenewswire.comFulcrum Digital Champions Intelligence Amplification In AI EvolutionFebruary 24, 2025 | msn.comFulcrum Therapeutics (FULC) Projected to Post Earnings on TuesdayFebruary 24, 2025 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,330,000 shares, a decline of 7.3% from the January 15th total of 4,670,000 shares. Based on an average daily trading volume, of 826,100 shares, the days-to-cover ratio is presently 5.2 days.February 18, 2025 | marketbeat.comFulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ETFebruary 18, 2025 | globenewswire.comFulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on TuesdayFulcrum Therapeutics (NASDAQ:FULC) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comFulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline AdvancementFebruary 8, 2025 | seekingalpha.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comFulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 6, 2025 | globenewswire.comFulcrum Therapeutics Insider Ups Holding During YearFebruary 4, 2025 | finance.yahoo.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of "Hold" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given a consensus rating of "Hold" by the ten ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three haFebruary 3, 2025 | marketbeat.comThalassemia Market Research by Treatment Type, Type, Distribution Channel, and Region - Global Forecasts 2034-2034January 31, 2025 | uk.finance.yahoo.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Barclays PLCBarclays PLC increased its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 367.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 124,141 shares of the company's stock after buying an additional 97,565 shares duringJanuary 19, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Hold" by AnalystsShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been given an average rating of "Hold" by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a holdJanuary 9, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest UpdateFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 4,260,000 shares, a decline of 7.0% from the November 30th total of 4,580,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is currently 4.1 days.December 30, 2024 | marketbeat.comState Street Corp Boosts Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)State Street Corp raised its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 61.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,680,229 shares of the company's stock after purchasing an additiDecember 29, 2024 | marketbeat.comFulcrum Therapeutics rumor highlighted in Betaville alertDecember 24, 2024 | markets.businessinsider.comFulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years agoDecember 19, 2024 | finance.yahoo.comCharles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Charles Schwab Investment Management Inc. boosted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 223.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 569,185 sharesDecember 17, 2024 | marketbeat.comFulcrum sketching out future plans for Bridge District in West SacramentoDecember 13, 2024 | bizjournals.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLCFmr LLC lessened its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 67.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,724,015 shares of the company's stock after selling 3,605,931 shDecember 13, 2024 | marketbeat.com202,030 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Purchased by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 202,030 shares of the company's stock, valued at approximately $721,000. Jacobs Levy EqDecember 10, 2024 | marketbeat.com20 Reasons Why Employees And Leaders Make Time For One-On-One MeetingsDecember 5, 2024 | forbes.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Position Reduced by RA Capital Management L.P.RA Capital Management L.P. trimmed its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 11.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,229,099 shares of the company's stock after seDecember 5, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires Shares of 132,784 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 132,784 shares of the companyNovember 30, 2024 | marketbeat.comBraidwell LP Purchases New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Braidwell LP acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,069,158 shares of the company's stockNovember 29, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Suvretta Capital Management LLCSuvretta Capital Management LLC decreased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 53.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,182,791 shares of the company's stock after selling 1,358,255 shareNovember 29, 2024 | marketbeat.comFulcrum Therapeutics (FULC) Upgraded to Buy: Here's WhyNovember 28, 2024 | msn.comFulcrum Therapeutics to Participate in Upcoming December ConferencesNovember 26, 2024 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Hold" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and threeNovember 20, 2024 | marketbeat.comResearch Analysts Issue Forecasts for FULC FY2024 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will postNovember 18, 2024 | marketbeat.comSimplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Simplify Asset Management Inc. reduced its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 47.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 351,314 shares of the company's stock after selling 323,518 sharesNovember 15, 2024 | marketbeat.comCautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic ShiftsNovember 15, 2024 | markets.businessinsider.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.020.51▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼184▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABCL News Today BCAX News Today CVAC News Today ORGO News Today ABUS News Today PRAX News Today NUVB News Today PHAR News Today LENZ News Today CRMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNew Way To Target 2x Trades Every Monday MorningNo. 1 Stock to Buy for THIS MONDAY Heads up: Tim Bohen’s new algorithm just uncovered a dirt-cheap stock th...StocksToTrade | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
